Connect Portal

  • Clinical Testing
    • OmniSeq INSIGHT
    • Order Test
    • Specimen Requirements
  • BioPharma Services
  • Publications
  • Patient Support
  • About
    • About
    • Leadership
    • News
    • Careers
    • Forms
    • Contact

Tumor Genetics & Cancer Research

by Felicia Lenzo | Nov 30, 2016 | News

Dr. Lucio Miele from LSU School of Medicine talks about the benefits of the recent partnership with OmniSeq on WVUE FOX 8 News in New...

OmniSeq Forms Clinical Evaluation Partnership with LSU Health New Orleans to Provide Comprehensive Genomic Profiling

by Felicia Lenzo | Nov 10, 2016 | News

NEW ORLEANS, LOUISANA – November 10, 2016 – Louisiana State University Health Sciences Center New Orleans ( LSU Health New Orleans) and Omniseq (OmniSeq®), a subsidiary of the Roswell Park Cancer Institute (RPCI), are now partnering to provide oncologists with...

OmniSeq Presents Benefits of Immune Cancer Profiling at Association of Molecular Pathology (AMP) with Thermo Fisher Scientific

by Felicia Lenzo | Nov 10, 2016 | News

THERMO FISHER SCIENTIFIC (TMO) EXPANDS PORTFOLIO OF NEXT-GENERATION SEQUENCING CANCER RESEARCH ASSAYS New Oncomine products enable immune response analysis of the tumor microenvironment, interrogation of BRCA 1-2 genes, and liquid biopsy research using cell-free DNA...

OmniSeq Appoints Genomics Industry Veteran Mark Gardner as CEO and Board of Directors Member

by Felicia Lenzo | May 29, 2016 | News

BUFFALO, N.Y., March 31, 2016 /PRNewswire/ — OmniSeq LLC today announced the appointment of biotech industry veteran Mark Gardner as CEO and member of its Board of Directors. His role will be effective in April after he transitions from his executive management post...

OmniSeq Aims to Change the Landscape of Cancer Treatment Through Unparalleled Diagnostic Precision, Therapeutic Knowledge and Peer-to-Peer Collaboration

by Felicia Lenzo | Sep 10, 2015 | News

OmniSeq℠ Aims to Change the Landscape of Cancer Treatment Through Unparalleled Diagnostic Precision, Therapeutic Knowledge and Peer-to-Peer Collaboration Buffalo, NY – June 11, 2015 – OmniSeq, LLC today announced that it has officially begun its spin out from Roswell...
« Older Entries

Follow Us on Twitter

OmniSeq Follow

Finding the right drug or the right trial...for every #cancer patient. #immunotherapy Pronounced OmniSeek

Avatar
Avatar OmniSeq @omniseq ·
24 Feb

Thank you to the many OmniSeq partners and followers who have been a part of our community! We appreciate your support and are looking forward to continuing the conversation around cancer diagnostics now that OmniSeq is part of Labcorp. Join us here: http://spr.ly/60113sQzZ

Reply on Twitter 1629118955485814785 Retweet on Twitter 1629118955485814785 Like on Twitter 1629118955485814785 2 Twitter 1629118955485814785
Avatar OmniSeq @omniseq ·
25 Jan

OmniSeq® is now part of Labcorp. Be sure to follow Labcorp to stay up-to-date on the latest #oncology updates. We look forward to providing timely and relevant information about how we are driving precision cancer care forward: https://bit.ly/3BdrZUu

Reply on Twitter 1618262421751173121 Retweet on Twitter 1618262421751173121 Like on Twitter 1618262421751173121 1 Twitter 1618262421751173121
Avatar OmniSeq @omniseq ·
4 Nov

This December, Dr. Sarabjot Pabla joins the speaker lineup for the TIGIT Axis Therapies Digital Summit. His presentation will focus on TIGIT RNA expressions and their impact in precision oncology medicines. Register for the virtual event today: https://bit.ly/3NAKg3S

Reply on Twitter 1588584498606014465 Retweet on Twitter 1588584498606014465 Like on Twitter 1588584498606014465 Twitter 1588584498606014465
Avatar OmniSeq @omniseq ·
3 Jun

LABCORP EXPANDS ACCESS TO COMPREHENSIVE GENOMIC TESTING THROUGH NEW LUNG CANCER PROGRAM UTILIZING OmniSeq INSIGHT
https://tinyurl.com/59xf82c6
@OmniSeq
@Labcorp
#oncology
#precisionmedicine

Reply on Twitter 1532751537994342401 Retweet on Twitter 1532751537994342401 Like on Twitter 1532751537994342401 5 Twitter 1532751537994342401
Avatar OmniSeq @omniseq ·
27 May

June 3-7 | Chicago, I Join us @ASCO 2022. LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers.
#2561-Developmental Therapeutics—Immunotherapy
Sunday, June 5, 8-11:00 AM CDT

Reply on Twitter 1530217104867196928 Retweet on Twitter 1530217104867196928 Like on Twitter 1530217104867196928 3 Twitter 1530217104867196928
Load More...

  • Facebook
  • Twitter
©2023 OmniSeq Corporation | Privacy Practices and Terms of Use. Regulatory   .